What Happened

Enlivex laid off 60% of its workforce, ended all preclinical R&D, and reduced executive salaries—including a 40% cut for CEO Oren Hershkovitz—to conserve cash. The company is now singularly focused on its phase 2b trial of allocetra, an off-the-shelf cell-based immunotherapy for knee osteoarthritis, expecting six-month topline data by mid-2027.

Who Is Affected

The layoffs hit roughly 20 employees out of 34, primarily in preclinical R&D and support roles. The management team took a uniform 20% salary reduction, while the CEO accepted a 40% cut. The clinical team remains intact to oversee the ongoing phase 2b study.

Market Impact

• Pipeline contraction: All non-clinical programs are paused, making Enlivex a pure-play on allocetra’s success.
• Cash runway extended: The restructuring ensures funding through the phase 2b readout, reducing near-term financing risk.
• Leaner operations: The company is now heavily reliant on external partners for any preclinical needs.
• Unique business model: Enlivex continues its prediction markets treasury strategy alongside the clinical focus, potentially attracting non-traditional investors.

What to Watch

The phase 2b topline data in mid-2027 is the single most important catalyst. Positive results could trigger partnership or licensing discussions; negative data would likely force a broader strategic review. The company’s unconventional dual model may also become a talking point for investors and analysts.

Related coverage

• GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
• GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam
• Enanta Pharmaceuticals lays off 37 employees ahead of key antiviral and immunology readouts
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data